ViiV says its HIV PrEP therapy outperformed Gilead's lenacapavir in early-stage trial
Source: SeekingAlpha
2025-10-15 07:49:59 ET
More on Pfizer, GSK, etc.
- GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
- Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)
- GSK's Hidden Growth Engines Beyond HIV And Oncology
- Pfizer CEO touts China's 'dramatic speed' in biopharma, calls for U.S. collaboration
- Pfizer continued losses for seven consecutive sessions
Read the full article on Seeking Alpha
For further details see:
ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial
Shionogi & Co Ltd
NASDAQ: SGIOF
SGIOF Trading
0.0% G/L:
$23.105 Last:
800 Volume:
$25.373 Open:
